Emerging Targeted Therapies Offer Efficacy Advantages Over Currently Used Chemotherapies for Platinum-Resistant Advanced Ovarian Cancer
Overall Survival and Delayed Disease Progression is the Greatest Unmet Need in Platinum-Resistant Advanced Ovarian Cancer, According to a New Report from Decision Resources
BURLINGTON, Mass., June 10, 2013 /PRNewswire/ — Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that the effect of an emerging therapy on key efficacy endpoints, including time to disease progression and overall survival, has the most influence over surveyed U.S. and European oncologists’ prescribing decisions for platinum-resistant advanced ovarian cancer. The emerging agents for this indication–Roche/Genentech/Chugai’s Avastin (which is already approved in Europe for recurrent platinum-sensitive ovarian cancer), Amgen/Takeda Pharmaceutical’s trebananib, Merck/Endocyte’s vintafolide and AstraZeneca’s olaparib–are all expected to offer efficacy advantages over currently available therapies used to treat platinum-resistant advanced ovarian cancer.
The Decision Base 2013 report entitled Ovarian Cancer (Platinum-Resistant Advanced): Are Emerging Targeted Therapies Poised to Fill the Significant Unmet Need for This Difficult-to-Treat Patient Population?, finds that surveyed U.S. oncologists would prescribe Avastin in combination with either weekly paclitaxel (Bristol-Myers Squibb’s Taxol, generics) or Janssen Biotech’s Doxil/Caelyx to a total of 55 percent of their drug-treated patients with platinum-resistant advanced ovarian cancer.
The report also finds that surveyed managed care organization (MCO) pharmacy directors are receptive to novel therapies that offer an improvement in progression-free survival (PFS) in this patient population. Based on clinical data and thought-leader opinion, Avastin in combination with chemotherapy is in position to offer the PFS benefit that the majority of surveyed U.S. payers indicated would be necessary for widespread inclusion on MCO formularies.
“The platinum-resistant advanced ovarian cancer population represents a patient population with high unmet need,” said Decision Resources Senior Analyst Gemma McConnell, Ph.D. “Current treatment consists of a non-platinum chemotherapy monotherapy, which typically result in low tumor response rates and a short progression-free interval. Taking together positive Phase III clinical data and interviewed experts’ opinion, Avastin in combination with chemotherapy is poised to address this unmet need.”
About Decision Resources
Decision Resources ( www.decisionresources.com ) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
SOURCE Decision Resources